Page Image

The Uromigos

The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.

ASCO

Latest Episode

Episode 336: Which Patients Are Not Suitable for 1st Line EVP in Bladder Cancer?
Dr. Jonathan Rosenberg and a surprise guest discuss comorbidities and treatment-related side effects linked to the use of EV/pembro in bladder cancer, as well as the criteria needed o receive this treatment. ...
Advertisement
Advertisement

The Uromigos: Live and Unplugged 2023

Kidney Cancer Discussions

Dr. Brian Rini’s Disclosures

Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis

Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai

Stock: PTC therapeutics

Advertisement
Advertisement
Get updates from The Uromigos straight to your inbox.